InVisionFirst®-Lung, a ctDNA NGS liquid biopsy is a 37-gene next-generation sequencing assay performed on cell-free circulating tumor DNA in peripheral blood to detect oncogenic driver mutations and therapy targets in non-small cell lung cancer (NSCLC). This assay demonstrated 98% concordance with tissue in clinical validation. Testing is performed by Inivata.
Non Small Cell Lung Cancer
ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase)
See More ...
Circulating Tumor DNA (ctDNA)
Confirmatory trial(s)